Why Diversity in Trials Is Doomed Until We Fix Reimbursement with Sam Whitaker
Listen now
Description
In this episode of 'Trials with Maya Z', host Maya Z interviews Sam Whitaker from Mural Health, discussing the pressing issue of patient reimbursement in clinical trials.  Sam Whitaker is a Founder and CEO of Mural Health, a tech company on a mission to make it easy to participate in clinical research. Mural Health was founded in 2022 as Sam’s effort to evolve the product he invented, the ClinCard, when he founded Greenphire in 2008. Maya and Sam explore how one-third of Americans are excluded from participating in clinical trials due to financial constraints and eligibility for welfare programs. The dialogue highlights the need for the clinical research industry to address financial barriers. Here are the topics Maya and Sam deep dive into: 01:03 Introducing Sam Whitaker: The Man Behind a Great Mission 03:01 The Reimbursement Dilemma: How It Affects Patient Diversity in Clinical Trials 20:30 Exploring Solutions: Legislative Efforts and Centralized Reimbursement Models 31:15 Empowering Change: How You Can Support and The Ideal World for Clinical Trials   Sign the letter to Congress and support Sam’s mission. Tune in today for a thrilling journey into the world of clinical trials – expand your knowledge!  Maya Zlatanova, CEO of Trialhub Sam Whitaker,  CEO of Mural Health See More: TrialHub Mural Health
More Episodes
How can we harness the power of AI to create more patient-centric clinical trials? Can technology and empathy coexist in healthcare? In this episode, Maya meets Stefan to explore the integration of artificial intelligence in clinical trials.  Stefan and his team at Enroll With assist clients in...
Published 05/08/24
In this episode, Maya meets Gretchen Knoll. She has over 20 years of experience in pharmaceutical clinical development, now she focuses on enhancing care for severely ill patients and reducing healthcare costs through strategic collaborations.  Maya and Gretchen Knoll discuss the challenges and...
Published 04/17/24
Published 04/17/24